UY26454A1 - Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida - Google Patents
Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituidaInfo
- Publication number
- UY26454A1 UY26454A1 UY26454A UY26454A UY26454A1 UY 26454 A1 UY26454 A1 UY 26454A1 UY 26454 A UY26454 A UY 26454A UY 26454 A UY26454 A UY 26454A UY 26454 A1 UY26454 A1 UY 26454A1
- Authority
- UY
- Uruguay
- Prior art keywords
- tetrahydrokinoline
- carboxamine
- substituted crystal
- crystals
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26454A1 true UY26454A1 (es) | 2001-07-31 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26454A UY26454A1 (es) | 1999-11-30 | 2000-11-28 | Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (fr) |
JP (1) | JP2003515592A (fr) |
KR (1) | KR20020058057A (fr) |
CN (1) | CN1402711A (fr) |
AP (1) | AP2002002531A0 (fr) |
AU (1) | AU1048801A (fr) |
BG (1) | BG106854A (fr) |
BR (1) | BR0015836A (fr) |
CA (1) | CA2392979A1 (fr) |
CO (1) | CO5271716A1 (fr) |
EA (1) | EA200200510A1 (fr) |
EC (1) | ECSP003792A (fr) |
EE (1) | EE200200277A (fr) |
GT (1) | GT200000199A (fr) |
HU (1) | HUP0203521A2 (fr) |
IL (1) | IL149097A0 (fr) |
IS (1) | IS6338A (fr) |
MA (1) | MA26845A1 (fr) |
MX (1) | MXPA02005354A (fr) |
NO (1) | NO20022558D0 (fr) |
OA (1) | OA12099A (fr) |
PA (1) | PA8506301A1 (fr) |
PE (1) | PE20010904A1 (fr) |
PL (1) | PL355892A1 (fr) |
TN (1) | TNSN00231A1 (fr) |
TR (1) | TR200201446T2 (fr) |
UY (1) | UY26454A1 (fr) |
WO (1) | WO2001040190A1 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
BR0210505A (pt) | 2001-06-21 | 2004-05-18 | Pfizer Prod Inc | Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo |
GT200200170A (es) | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
EP1920766B1 (fr) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles |
BR0307333A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização |
WO2004020393A1 (fr) | 2002-08-30 | 2004-03-11 | Japan Tobacco Inc. | Compose dibenzylamine et utilisation medicinale de ce compose |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
AU2003277285B2 (en) | 2002-10-04 | 2007-12-13 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
ATE461700T1 (de) | 2002-12-20 | 2010-04-15 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
CA2520405A1 (fr) * | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | Derives de 1,2,3,4-tetrahydro- et 1,2 dihydro-quinoleine et 1,2,3,4-tetrahydro-quinoxaline 1,2,4-substitues, utiles comme inhibiteurs de cetp pour le traitement de l'atherosclerose et de l'obesite |
WO2005011635A2 (fr) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles |
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
CN1942428A (zh) * | 2004-04-13 | 2007-04-04 | 默克公司 | Cetp抑制剂 |
MXPA06014716A (es) * | 2004-06-24 | 2007-03-12 | Lilly Co Eli | Compuestos y metodos para el tratamiento de dislipidemia. |
US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
WO2006033001A1 (fr) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Composes de quinoline |
UA90706C2 (ru) | 2005-02-24 | 2010-05-25 | Милленниум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
WO2006098394A1 (fr) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
TW200901959A (en) | 2007-03-09 | 2009-01-16 | Indigene Pharmaceuticals Inc | Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (fr) | 2008-12-16 | 2010-07-01 | Schering Corporation | Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques |
AR077208A1 (es) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
WO2016016157A1 (fr) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Marqueurs génétiques pour la prédiction de la réactivité à une thérapie avec un agent d'augmentation de hdl ou d'imitation de hdl |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (fr) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | Derives de l'-1-acyl-1,2-dihydroquinoline substituee en 2 augmentant la concentration en cholesterol hdl |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/fr not_active Abandoned
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/fr not_active Application Discontinuation
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 EP EP00971662A patent/EP1246804A1/fr not_active Withdrawn
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558D0/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
CO5271716A1 (es) | 2003-04-30 |
TR200201446T2 (tr) | 2002-11-21 |
EE200200277A (et) | 2003-10-15 |
HUP0203521A2 (hu) | 2003-02-28 |
NO20022558L (no) | 2002-05-29 |
PA8506301A1 (es) | 2002-08-26 |
AP2002002531A0 (en) | 2002-06-30 |
AU1048801A (en) | 2001-06-12 |
NO20022558D0 (no) | 2002-05-29 |
KR20020058057A (ko) | 2002-07-12 |
BG106854A (bg) | 2002-12-29 |
IL149097A0 (en) | 2002-11-10 |
PL355892A1 (en) | 2004-05-31 |
IS6338A (is) | 2002-04-12 |
WO2001040190A1 (fr) | 2001-06-07 |
OA12099A (en) | 2006-05-04 |
MA26845A1 (fr) | 2004-12-20 |
GT200000199A (es) | 2002-05-23 |
CN1402711A (zh) | 2003-03-12 |
EP1246804A1 (fr) | 2002-10-09 |
EA200200510A1 (ru) | 2002-10-31 |
CA2392979A1 (fr) | 2001-06-07 |
JP2003515592A (ja) | 2003-05-07 |
TNSN00231A1 (fr) | 2002-05-30 |
PE20010904A1 (es) | 2001-09-10 |
ECSP003792A (es) | 2002-04-23 |
BR0015836A (pt) | 2002-08-06 |
MXPA02005354A (es) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26454A1 (es) | Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida | |
ES2090713T3 (es) | Sales organicas de n,n'-diacetil-cistina. | |
UY24555A1 (es) | Nuevos compuestos | |
AR011069A1 (es) | Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible. | |
ES2053451T3 (es) | Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles. | |
GT199900102A (es) | Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen. | |
WO2003062259A3 (fr) | Nouveaux composes | |
ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
DK1007520T3 (da) | 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer | |
AR023777A1 (es) | Nuevos compuestos | |
ES2133543T3 (es) | Derivados de pirrolidina y oxazolidina, su preparacion y su uso como inhibidores de la agregacion de trombocitos. | |
AR021355A1 (es) | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento | |
ES2134801T3 (es) | Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso. | |
NO934628L (no) | Retrovirus-protease-inhibitorer | |
PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
ECSP034531A (es) | Derivados sustituidos de c-ciclohexilmetilamina | |
DK0391171T3 (da) | Anvendelse af di-styryl-phenyl-triglycolether som krystallisationsinhibitor | |
HN2001000235A (es) | Derivados puentes de piperazina | |
DK1051177T3 (da) | Steroide 3-O-Sulfamatderivater som inhibitorer af östronsulfatase | |
ES2186989T3 (es) | Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion. | |
BR9814495A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo | |
PA8495001A1 (es) | Nuevas formas cristalinas de un antibiotico macrolido. | |
MX9400165A (es) | Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen. | |
MX9200874A (es) | Compuestos de una composicion especifica, un procedimiento para su produccion y su uso. | |
ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20120529 |